

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

TF-1

RRID:CVCL_0559

Type: Cell Line

Proper Citation

RRID:CVCL_0559

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0559

Proper Citation: RRID:CVCL_0559

Description: Cell line TF-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Erythroleukemia

Defining Citation: [PMID:1571549](#), [PMID:2656885](#), [PMID:2663885](#), [PMID:9096695](#), [PMID:9510473](#), [PMID:11021758](#), [PMID:11414198](#), [PMID:16408098](#), [PMID:22460905](#), [PMID:23955599](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:36982453](#)

Comments: Characteristics: IL3 or CSF2 dependent., Characteristics: Proliferatively responsive to many growth factors., Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: TF-1

Synonyms: TF1, MFD-1

Cross References: BTO:BTO_0004760, CLO:CLO_0009325, CLO:CLO_0009326, EFO:EFO_0022398, MCCL:MCC:0000460, CLDB:cl4503, CLDB:cl7163, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CRL-2003, BCRC:60323, BCRJ:0233, BioGRID_ORCS_Cell_line:219, BioSample:SAMN03470850, BioSample:SAMN10988443, cancercellines:CVCL_0559,

CCRID:1101HUM-PUMC000118, CCRID:1102HUM-NIFDC00101, CCTCC:GDC0196, Cell_Model_Passport:SIDM01470, ChEMBL-Cells:ChEMBL3307972, ChEMBL-Targets:ChEMBL612552, CLS:300434, Cosmic:787479, Cosmic:919129, Cosmic:924041, Cosmic:975302, Cosmic:1012123, Cosmic:1127259, Cosmic:1281355, Cosmic:2089658, Cosmic:2306240, DepMap:ACH-000387, DSMZ:ACC-334, DSMZCellDive:ACC-334, ECACC:93022307, GDSC:1331044, GEO:GSM743414, GEO:GSM887704, GEO:GSM888797, GEO:GSM1374961, IARC_TP53:2197, ICLC:HTL05001, LiGeA:CCLE_592, LINCS_LDP:LCL-1077, Lonza:1015, NCBI_Iran:C602, PharmacDB:TF1_1588_2019, Progenetix:CVCL_0559, PubChem_Cell_line:CVCL_0559, Wikidata:Q54972197

ID: CVCL_0559

Record Creation Time: 20220427T221624+0000

Record Last Update: 20260830T000104+0000

Ratings and Alerts

No rating or validation information has been found for TF-1.

Warning: Discontinued: BCRJ; 0233

Characteristics: IL3 or CSF2 dependent., Characteristics: Proliferatively responsive to many growth factors., Population: Japanese., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 191 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Clayfield L, et al. (2026) Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell reports, 45(2), 116875.

Kim M, et al. (2026) MiR-513a promotes human erythroid differentiation by modulating c-Jun. FEBS open bio, 16(8), 1509.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.

Pereira-Martins DA, et al. (2026) ?Np73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. Cell reports. Medicine, 102540.

Hilgart E, et al. (2026) DNA Methylation Stochasticity Is Linked to Transcriptional Variability and Convergent Epigenetic Disruption across Genetic Subtypes of Acute Myeloid Leukemia. *Cancer research*, 86(13), 3325.

Ahn JH, et al. (2025) JAK-STAT inhibitory effect of IN-115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine. *British journal of pharmacology*, 182(20), 5071.

Chancellor A, et al. (2025) The carbonyl nucleobase adduct M3Ade is a potent antigen for adaptive polyclonal MR1-restricted T cells. *Immunity*, 58(2), 431.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. *Cell stem cell*, 32(3), 463.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. *Nature communications*, 16(1), 7793.

Ben-Crentsil NA, et al. (2024) RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. *Cancer discovery*, 14(12), 2509.

Lu MJ, et al. (2024) SLC25A51 decouples the mitochondrial NAD⁺/NADH ratio to control proliferation of AML cells. *Cell metabolism*, 36(4), 808.

Chang YH, et al. (2024) SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiation. *Cell reports*, 43(8), 114536.

Lyu J, et al. (2023) Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance. *Cancer discovery*, 13(1), 170.

Hsu YH, et al. (2023) Using brain cell-type-specific protein interactomes to interpret neurodevelopmental genetic signals in schizophrenia. *iScience*, 26(5), 106701.

Pouyan P, et al. (2023) One to one comparison of cell-free synthesized erythropoietin conjugates modified with linear polyglycerol and polyethylene glycol. *Scientific reports*, 13(1), 6394.

Nelson MH, et al. (2023) The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies. *Molecular cancer therapeutics*, 22(1), 89.

Ren JG, et al. (2023) RAB27B controls palmitoylation-dependent NRAS trafficking and signaling in myeloid leukemia. *The Journal of clinical investigation*, 133(12).

Rivera KO, et al. (2023) Encapsulation of ?-NGF in injectable microrods for localized delivery accelerates endochondral fracture repair. *Frontiers in bioengineering and biotechnology*, 11, 1190371.

Hart ML, et al. (2023) Mitochondrial redox adaptations enable alternative aspartate synthesis in SDH-deficient cells. *eLife*, 12.

Letson CT, et al. (2023) Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. *Clinical cancer research : an official journal of the*

American Association for Cancer Research, 29(15), 2919.